Dataset Information

Synergistic Inhibition of PI3K and HSP90 Enhanced Antitumorigenic Efficacy in Adrenocortical Carcinoma

ABSTRACT: Adrenocortical cancer (ACC) is a rare and aggressive malignancy with poor survival due to a lack of effective treatments; therefore, it is important to identify therapies that can be readily studied in clinical trials. Quantitative high-throughput drug combination screening identified potent synergy between phosphatidylinositol-3-kinase (PI3K) inhibition and heat shock protein 90 (HSP90) inhibition. This GEO submission contains the 18 bulk RNA-seq samples from NCI-H295R ACC cells that were used in the publication to evaluate transcriptional responses to PI3K and HSP90 inhibitors alone and in combination. The submitted samples include untreated controls and cells treated with STA9090, PIK75, BGT226, STA9090+PIK75, or STA9090+BGT226, with three biological replicates per condition. These RNA-seq data supported the comparison of molecular responses induced by PI3K/HSP90 inhibitor combinations in ACC cells, including distinct responses associated with PIK75+STA9090 and BGT226+STA9090 treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE330925 | GEO | 2026/07/23

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:The molecular pathogenesis of adrenocortical diseases, particularly adrenocortical carcinoma (ACC), has advanced considerably in recent years due to the application of high-throughput molecular analysis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers an approach for identifying and quantifying numerous proteins in biological samples. Aiming to identify differences in adrenal cortex disease protein signatures that may contribute to understanding their distinct pathogenesis, we used LC-MS/MS and bioinformatics analysis to compare the proteomic profiles of normal human adrenal samples (NHA), adrenocortical adenomas (ACA), adrenocortical carcinomas (ACC), and primary macronodular adrenocortical hyperplasia (PMAH) tumor samples, with (w) and without (wt) ARMC5 mutation. A total of 7,350 proteins were identified, with 3,976 proteins quantified in all analyzed samples, and differentially expressed proteins (DEPs) noted as upregulated and downregulated were highlighted as relevant. We identified 27 DEPs in ACA vs. NHA, where MT3 and RBM3 are upregulated, and NEFL, HAAO, SOD3, IGHA2, and HDGFL3 are the top five of 25 downregulated proteins; 49 DEPs in ACC vs. NHA, with DEFA3, NUP160, SRRM2, and RBM3 upregulated, alongside SOD3, CNRIP, DNAH1, GAMT, ADIRF, and CA3 as the top six of 45 downregulated proteins; 81 DEPs in PMAH vs. NHA, with RBM3, RIGI, SPAG9, and SRRM2 proteins as the top four of 9 upregulated proteins, and 72 downregulated proteins with AFM, CA 3, IGKV1-5, ADIRF, and LRG1 as the top five; ACC vs. ACA identified 64 upregulated and 48 downregulated DEPs, with PHGDH (SERA), PDCD4, MAGED2, ERAP2, FTO, DUSP23, UBLCP 1, NSUN2, TP53BP1, NUP107 as the top ten upregulated, and RMDN2, CSRP1, ACAD11, PACSIN3, HAGH (GLO2), ALG5, NEXN, ABLIM1, LBP, and SYNPO2 as the top ten downregulated in ACC. DEPs analysis in PMAHw vs. PMAHwt showed the lowest number of DEPs, with NOSTRIN, PCP4, C4 BPB, and SERB (PSPH) as the top four of 12 upregulated proteins, and 4 downregulated proteins EST2 (TERT), PNPT1, RDH13, and STAB1 in PMAHw. Comparative analysis highlighted several targets for functional analysis and validation to determine the mechanism of action and protein biomarkers.

Dataset Information

Synergistic Inhibition of PI3K and HSP90 Enhanced Antitumorigenic Efficacy in Adrenocortical Carcinoma

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets